Apr 20, 2015

1) How C90orf72 promotor hypermethylation is neuroprotective and 2) Topic of the month: Implementation of genetic testing. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Corey McMillan about his paper on how C90orf72 promotor hypermethylation is neuroprotective. Dr. Sarah Wesley is reading our e-Pearl of the week about paraneoplastic cerebellar degeneration. In the next part of the podcast Dr. Ted Burns interviews Dr. Daniel MacArthur about the variants of unknown significance. The participants had nothing to disclose except Drs. Burns, McMillan and Wesley.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with CSL Behring and Alexion Pharmaceuticals, Inc.Dr. McMillan received payment for being plenary speaker at the 2015 International Conference on Frontotemporal Degeneration; and receives research support from the NIH.Dr. Wesley serves on the editorial team for the Neurology® Resident and Fellow Section.